William Weintraub
Cardiovascular Disease · Newark, DENPI 1467489146
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,416 of the $24,025 with a category attached, or 80.8%. AstraZeneca accounts for 66.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $12,308 and has fallen 98.2% since, to $218 in 2025.
Across 57 payments — averaging $421.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$16K
- Amarin Pharma, Inc.$7K
- Medtronic$482
- Abbott$295
- Boston Scientific$215
- Novartis$72
- plus $93 from 3 others
Across 19 payments — averaging $67,903 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amarin Pharma, Inc.$968K
- Lexicon Pharmaceuticals, Inc.$323K
What the payments were for
- Consulting fees$19,41681%
- Travel & lodging$2,67111%
- Food & beverage$1,9398%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $16,041 |
| Amarin Pharma, Inc. | 19 | $6,826 |
| Medtronic | 5 | $482 |
| Abbott | 5 | $295 |
| Boston Scientific | 4 | $215 |
| Novartis | 3 | $72 |
| Impulse Dynamics (USA) Inc. | 1 | $38 |
| Pfizer | 2 | $31 |
| Amgen | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$6,300
- CRESTOR$4,296
- Micra$203
- PulseSelect$142
- COBALT DR MRI SURESCAN$115
How this compares
$24,025 in reported general payments places this provider in the 85th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Newark
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Anthony AlfieriNewark$45K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Anthony ClayNewark$37K
- Ashish ParikhNewark$26K
- Wen Chi TsaiNewark$20K
- Stephen MengNewark$17K
- Francis PalermoNewark$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.